Full Breakdown
Investigating the Removal of Abortion Pill Safety Protocols
2/19/2026, 9:14:56 PM
Core Event: Changes to Mifepristone Safety Regulations
The removal of safety protocols for the abortion pill mifepristone, also known as Mifeprex, has raised questions regarding the financial influences behind these regulatory changes. In 2016, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application from Danco Laboratories, which loosened the existing Risk Evaluation and Mitigation Strategies (REMS) for mifepristone. This decision has been scrutinized for its implications on abortion access and safety.
Background & Context: The Evolution of Mifepristone Regulations
Mifepristone was approved by the FDA in 2000 under a REMS program designed to monitor its safety. In 2015, Danco Laboratories reportedly lacked the funds to pursue changes to these safety protocols. However, by 2016, the company secured funding to file a supplemental application, leading to significant modifications in the REMS, including the removal of in-person requirements for administering the drug and the expansion of its use from seven to ten weeks of pregnancy.
Key Figures & Groups: Influential Organizations
The Coalition to Improve Access to Mifepristone, founded in 2015, played a crucial role in advocating for the loosening of safety restrictions. This coalition included organizations such as Planned Parenthood, NARAL, and Gynuity Health Projects. Notably, the Susan Thompson Buffett Foundation and the David and Lucile Packard Foundation have been identified as significant financial backers of both Danco and initiatives aimed at expanding abortion access.
Official Statements & Responses
Carrie Baker, author and expert on the history of abortion pills, noted that while Danco initially expressed no issues with the REMS, the coalition's advocacy led to a shift in their stance. Baker emphasized that the coalition helped Danco raise funds necessary for the supplemental application. Danco's spokesperson, Mitchell Creinin, claimed that the company actively sought to remove the REMS but faced resistance from the FDA, which was concerned about political backlash.
Criticism & Opposition: Concerns Over Safety and Transparency
Critics argue that the removal of safety protocols compromises patient safety and opens the door to potential misuse of the drug. Pro-life organizations have raised alarms about the implications of the FDA's decisions, questioning the transparency of the funding sources that supported Danco's application. Concerns have also been voiced regarding the potential conflicts of interest among organizations advocating for the changes.
Conflicting Reports & Gaps: Discrepancies in Perspectives
There are conflicting views on whether Danco actively sought to remove the REMS. While some coalition members believed that Danco was hesitant to push for full removal due to commercial advantages, others, including Creinin, assert that Danco fought hard for these changes. The lack of clarity surrounding the funding sources for Danco's supplemental application remains a significant gap in the narrative.
Verbatim Quotes
- “but the FDA made it really clear throughout the whole process the REMS was not going away.” — Mitchell Creinin, Danco Laboratories
- “They didn’t have a problem with the restrictions.” — Francine Coeytaux, Plan C
- “Feb 11, 2026, 5:50 PM ET Dear FDA: Who paid for the removal of abortion pill safety protocols?” — Live Action News
The ongoing debate surrounding the safety protocols for mifepristone highlights the complex interplay of advocacy, funding, and regulatory decisions in the realm of reproductive health.
